SOFIE Biosciences, a Dulles, VA-based radiopharmacy and contract development and manufacturing organization, received a strategic growth investment from Trilantic North America.
The amount of the deal was not disclosed. The investment was made in partnership with SOFIE’s founding team, who will retain a meaningful equity stake and continue to lead the business.
The company intends to use the funds to accelerate its growth initiatives, including expanding capacity and points of presence to improve patient access to its portfolio of radiopharmaceutical products.
Led by President and CEO Patrick Phelps, SOFIE aims to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics) via its radiopharmaceutical production and distribution network, mature contract manufacturing services, and Theranostic intellectual property.
The company operates 15 locations across the United States.
FinSMEs
05/06/2024